Business litigation services – Selagy Law http://selagylaw.com/ Tue, 12 Oct 2021 12:43:40 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://selagylaw.com/wp-content/uploads/2021/10/icon-1-120x120.png Business litigation services – Selagy Law http://selagylaw.com/ 32 32 California just signed the country’s toughest recycling labeling and marketing bill https://selagylaw.com/california-just-signed-the-countrys-toughest-recycling-labeling-and-marketing-bill/ Tue, 12 Oct 2021 12:08:49 +0000 https://selagylaw.com/california-just-signed-the-countrys-toughest-recycling-labeling-and-marketing-bill/ California is focusing its attention on increasing sustainable marketing, including recycling-centric claims through a new law that mandates the use of recycling labels – including the “arrow hunt” motif. According to the bill, which was enacted earlier this month by California Governor Gavin Newsom, unless a product or packaging is considered recyclable “in accordance with […]]]>

California is focusing its attention on increasing sustainable marketing, including recycling-centric claims through a new law that mandates the use of recycling labels – including the “arrow hunt” motif. According to the bill, which was enacted earlier this month by California Governor Gavin Newsom, unless a product or packaging is considered recyclable “in accordance with the criteria for world-wide recyclability. ‘Condition and whether it is of a type and form of material which regularly becomes raw materials used in the production of new products or packaging, “the use” of a chasing arrows symbol, among d ‘other symbols, statements [indicating the product is recyclable directly on the product], or instructions ”, will be considered misleading or misleading.

The new law – which amends sections 17580 and 17580.5 of the California Business and Professions Cod and calls on the state Department of Resources Recycling and Recovery to publish standards by January 1, 2024 regarding the types of materials / shapes considered recyclable – applies to all consumer goods and product packaging, unless otherwise specified. And it’s widely characterized as the country’s strictest standard for when items may (and may not) display the recycling symbol and any other representation advising consumers that a product or its packaging may be recycled.

The impact of the new recycling marketing law is limited in terms of applicability – at least directly – to products sold in the state of California. However, it is likely to have a significant effect on brands if only for the sheer size of the consumer goods market in California. Beyond that, experts expect the law to likely expand on a larger scale. In 2024, when the law goes into effect, “California’s new, stricter standard is likely to become the rule to follow when it comes to recyclability,” says Frankfurt Kurnit Klein & Selz lawyer Jordyn Eisenpress. And while the Federal Trade Commission ‘s Green Guides “provide federal level advice on environmental marketing, state environmental marketing laws offer a patchwork of restrictions, resulting in (as has been the case with legislation on privacy) in the largest, most restrictive states. set the tone for the entire space.

The California law is the first of its kind in the United States, although other states are in fact turning to recycling. Maine and Oregon have passed laws that require companies to foot the bill for the cost of recycling their packaging, with the Oregon legislature planning to establish a task force to tackle potentially “deceptive or” issues. confusing ”. [recycling] complaints ”related to recycling. At the same time, a bill relating to “false claims regarding recyclability and labeling of plastic containers” is pending in the New York Senate.

Meanwhile, the UK’s Competition & Markets Authority recently released its much-anticipated Green Claims Code, the competition and consumer protection regulator providing advice to companies making environmental claims. The new Code ”- which aims to“ help businesses understand and comply with their existing obligations under consumer protection law when making environmental claims ”- applies to all businesses everywhere. market sectors and extends to claims made in advertisements, product labeling and packaging or other accompanying information, including product names, and presumably, any logos or graphics that are used in relation to business goods / services.

The rise of “green” brands

The wave of activity comes as businesses continue to capitalize on growing consumer sentiment about the need to consume more consciously through often comprehensive sustainability campaigns and without a shortage of eco-buzzwords. Unsurprisingly, the widespread adoption of sustainability-focused marketing messages by brands at all levels – from fast and high fashion brands to beauty brands and consumer packaged goods companies – has led to an increase in misleading and / or unfounded claims, and a multitude of confused consumers.

It will be interesting to see how far the impending crackdown on recycling – and other ‘green’ symbols and advertising language – goes – as companies have been working overtime to address growing consumer climate concerns. The result goes beyond dedicated marketing campaigns and specific “green” products (such as collections of recycled capsules), and also comes in the form of a growing number of “green” brand registrations around the world. . The European Union Intellectual Property Office (“EUIPO”), for example, disclosed in a report last month that more than 2 million applications to register what she calls the “green mark” have been filed since 1996, with the volume of marks mentioning “green terms”, such as recycling, “increasing significantly at the both in absolute numbers and as a proportion of all EU trademark filings.

“The main finding of the study,” according to EUIPO, is that “environmental considerations are becoming increasingly important for trademark owners who file trademark applications and for consumers who purchase the products and services that apply them. result “.

Reflecting on EUIPO’s findings, Pinsent Masons Legal Director Désirée Fields said: “With climate change and environmental issues high on the political, business and debate agendas public, consumers increasingly seek to purchase products that are considered environmentally friendly and sustainable, [and] brands can play an important role in helping consumers identify that they are buying a product that meets these characteristics.

In addition to “certification marks, collective marks or warranty marks, which indicate to consumers that a product conforms to certain standards or characteristics”, Fields notes that companies have developed a habit of adopting marks which not only indicate to consumers that a product or service comes from a particular source, but that they are the result of “a business which, usually through heavy investment in marketing and consumer education by the brand owner, has come to be recognized as “green brands”. ”

In this vein, brands that suggest elements of sustainability, such as recycling, are also on the rise. Prada, for example, has filed claims this year for a brand which consists of the word Re-Prada as well as a stylized interpretation of its triangular logo to be used as part of its drive to use recycled nylon – or econyl, a proprietary material made from recycled industrial nylon waste such as netting. fishing and rugs – in its accessories offers. Meanwhile, Louis Vuitton also filed for registration with the United States Patent and Trademark Office for a trademark consisting of two twisted arrows that distinguish the letters “LV” for use on “upcycled” sneakers.

Brands like these are interesting in that they may not use the recycle symbol itself. However, they implicitly make sustainability-focused claims because of their appearance and therefore may be subject to things like the FTC’s green guides, for example, which apply to ‘environmental claims in labeling, advertising, promotional material and all other forms of marketing in any medium, whether affirmed directly or by implication, by words, symbols, logos, representations, product brand names or any other means .

“Investing and integrating environmental protection and sustainability into a company’s brand [growth and] Protection strategy can add value, ”said Fields, given that“ there is so much attention on these important issues globally ”. While this remains true in light of the growing crackdown by regulators on deceptive sustainability marketing, including claims of “overall environmental benefit” – and the willingness of consumers and independent watchdogs to call brands and / or take legal action in some cases, brands would be wise to consider the balance between the benefits of such branding and the potential ramifications.


Source link

]]>
Business Updates in Teller County October 13, 2021 | Pikes Peak Courier https://selagylaw.com/business-updates-in-teller-county-october-13-2021-pikes-peak-courier/ Tue, 12 Oct 2021 12:08:21 +0000 https://selagylaw.com/business-updates-in-teller-county-october-13-2021-pikes-peak-courier/ The Business Buzz features economic news, promotions, acquisitions and expansions. Contact Pat Hill at pat.hill@pikespeaknewspapers.com or 686-6458. CORE Electric Cooperative announces Joan Beckner as General Counsel CORE Electric Cooperative, an electric cooperative based in Sedalia, has announced the hiring of Joan Beckner as General Counsel, effective October 4. Beckner’s experience in the energy industry spans […]]]>

The Business Buzz features economic news, promotions, acquisitions and expansions. Contact Pat Hill at pat.hill@pikespeaknewspapers.com or 686-6458.

CORE Electric Cooperative announces Joan Beckner as General Counsel

CORE Electric Cooperative, an electric cooperative based in Sedalia, has announced the hiring of Joan Beckner as General Counsel, effective October 4.

Beckner’s experience in the energy industry spans business-oriented legal and engineering roles. She specialized for 10 years in the Houston office of a large international law firm before spending 5 years leading various legal teams at Schlumberger. His solid technical background will allow him to understand our operations and offer practical solutions to manage legal risk.

Beckner received his BS and MS in Petroleum Engineering from Stanford University and JD from the University of Houston Law Center. Most recently, Beckner completed the Professional Certificate Program in Clean Energy Financing and Deployment at the Yale Center for Business and the Environment as a member of his 2020-21 cohort.

Change of brand from IREA to CORE Electric Cooperative

The Intermountain Rural Electric Association announced in late August that it is now CORE Electric Cooperative, a name and identity that reflects its mission of providing essential electrical service to thriving communities and its role at the center of the life of a modern membership. and diverse.

The company will remain structured as a not-for-profit, member-owned cooperative electricity utility serving Colorado.

“We’re just a different company today than where we were originally,” said Tim White, chairman of the board, in a statement. “We are at the heart of the lives of our members. The communities we serve are located in CORE – the central part – of Colorado. “

CORE, formerly IREA, began over 80 years ago providing electrical service primarily to rural communities. Since then, it has grown into Colorado’s largest electricity distribution cooperative, serving some 300,000 customers. Its 5,000 square mile footprint now extends beyond mountains and rural areas to some of America’s most vibrant communities.

This rebranding is not the result of a merger or acquisition. Billing and services will remain the same, so members do not need to take any action or make any changes due to this rebranding.

Member service remains the same at 800-332-9450.

For more information, visit CORE.coop.

Also

Matt McCracken was unanimously elected treasurer by the board of directors of the Downtown Development Authority at a special meeting on October 8. McCracken owns McCracken Professional Builders in Woodland Park.

Wildwood Casino was the presenting sponsor of the 3rd Annual Light of Hope Teller, an October 6 fundraising breakfast for the Court-appointed Special Advocate in Teller County. Schommer Construction LLC was the Children’s Hero Circle sponsor for the event and Carter Realty and HD Aero were the Hope Circle sponsor.


Source link

]]>
Foley & Lardner is Salt Lake City’s latest big looking law firm https://selagylaw.com/foley-lardner-is-salt-lake-citys-latest-big-looking-law-firm/ Tue, 12 Oct 2021 12:02:41 +0000 https://selagylaw.com/foley-lardner-is-salt-lake-citys-latest-big-looking-law-firm/ Foley & Lardner opens office in Salt Lake City and adds intellectual property litigation team as part of its continued strategy to expand in key markets. The move, announced on Monday, comes weeks after Kirkland & Ellis announced it would also open an office in Salt Lake City. Large companies with deep pockets filled by […]]]>

Foley & Lardner opens office in Salt Lake City and adds intellectual property litigation team as part of its continued strategy to expand in key markets.

The move, announced on Monday, comes weeks after Kirkland & Ellis announced it would also open an office in Salt Lake City. Large companies with deep pockets filled by a pandemic flurry of work are looking to establish beachheads in new locations, especially those with a tech bent.

Salt Lake City is positioning itself as a hub for tech startups and venture capital transactions, with investors investing billions of dollars in start-ups. As these businesses grow, they seek an increasingly broad range of legal services.

“Salt Lake City is rapidly gaining ground as one of the nation’s premier tech and startup hubs, with a multitude of tech companies doing business in the metro area,” said Jay Rothman, chief executive officer by Foley.

Quinn Emanuel, the large Los Angeles-based litigation firm, has generated great interest in the city of Utah. She opened a site in 2018, offering patent litigation and other legal services. By 2020, 18 companies listed in the AmLaw 200 ranks had opened offices in Utah, double the number that existed in 2015. Dentons and Lewis Brisbois are among other companies that have planted flags in the state.

Foley added a team of four Dentons intellectual property attorneys last year, including the former co-head of the firm’s IP practice group.

The Milwaukee-based Foley also focuses on healthcare and life sciences. The company reported more than $ 922 million in gross revenue in 2020, ranking it among the top 50 companies in the country.

Foley is open to expansion to further add to its core legal expertise in the areas of business, health and life sciences and intellectual property, Rothman said.

“We want to serve a client who might come in, and the legal issue may not be clear,” he told Bloomberg Law. “We have a holistic approach and we will be ready to help them, whatever the sector or the market. “

Foley announced in 2018 that he was teaming up with Gardere Wynne Swell to give him a presence in Austin, Texas, as well as Dallas, Houston, Denver and Mexico City. The firm currently has approximately 1,100 lawyers in 25 offices around the world.

His new attorneys in Salt Lake City, partners David Wright and Jared Braithwaite, senior counsel Michael Manookin and special counsel Taylor Wright, were from Maschoff Brennan, an intellectual property litigation boutique, which has offices in California and in Utah.


Source link

]]>
Marten Law Adds Washington DC and Boston Offices | New https://selagylaw.com/marten-law-adds-washington-dc-and-boston-offices-new/ Tue, 12 Oct 2021 12:02:19 +0000 https://selagylaw.com/marten-law-adds-washington-dc-and-boston-offices-new/ SEATTLE – (BUSINESS WIRE) – October 12, 2021– Marten law is pleased to announce its expansion to the East Coast, with the addition of James pollack in Boston, MA, and Jack Lyman in Washington, DC The firm also announces the addition of Lawson Fite in Portland, OR, and Ana Nina in Seattle, WA. This press […]]]>

SEATTLE – (BUSINESS WIRE) – October 12, 2021–

Marten law is pleased to announce its expansion to the East Coast, with the addition of James pollack in Boston, MA, and Jack Lyman in Washington, DC The firm also announces the addition of Lawson Fite in Portland, OR, and Ana Nina in Seattle, WA.

This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20211012005292/en/

Lawson Fite, Portland, OR (Photo: Business Wire)

Lawson Fite joins Marten’s Portland office as an associate and co-chair of Marten’s natural resources practice. He draws on more than 15 years of experience in private practice and several years as Chief Counsel of a professional timber association. He has represented clients in more than 50 cases before federal and state trial and appellate courts, including the United States Supreme Court. He was legal assistant to Justice Walter L. Carpeneti of the Alaska Supreme Court and obtained his JD from Harvard Law School.

Jack Lyman established Marten’s office in Washington DC after more than 7 years of government and private practice. Jack has argued air, water and waste cases on behalf of federal agencies in the US Department of Justice. In private practice, Jack focuses on regulatory and transactional matters for customers in the chemical, manufacturing and energy fields, as well as litigation on behalf of transportation customers. He received his JD from the University of North Carolina Law School.

Ana Nina joins Marten’s Seattle office as a partner. Prior to obtaining her JD in the United States, Ana worked for many years as an environmental lawyer in Brazil and taught law in the United States and Brazil. At Marten, she advises clients on business transactions and regulatory enforcement matters. Ana received her JD from the Global Accelerated JD Program at Seattle University School of Law. She also holds a doctorate from Pontifical Catholic University-RJ and an LLM from Harvard Law School.

James pollack joins Marten’s Boston office as a partner. James advises his clients on the Clean Water Act, the Clean Air Act and the National Environmental Policy Act. He also advises technology clients on compliance, sustainability and ESG. Prior to joining Marten Law, James worked for Chief Justice Brian M. Morris of the United States District Court, Montana District in Great Falls, MT. He received his JD from Harvard Law School while also earning an MPP from the John F. Kennedy School of Government.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211012005292/en/

CONTACT: Keelin Kelly

206.612.3071

KEYWORD: MASSACHUSETTS DISTRICT OF WASHINGTON OF COLUMBIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ENERGY ENVIRONMENT PROFESSIONAL SERVICES LEGAL OTHER ENERGY

SOURCE: Marten Law

Copyright Business Wire 2021.

PUB: 12/10/2021 08: 00 / DISC: 12/10/2021 08:02

http://www.businesswire.com/news/home/20211012005292/en

Copyright Business Wire 2021.


Source link

]]>
Valvoline to Continue Separation of Retail Services and Global Products Businesses https://selagylaw.com/valvoline-to-continue-separation-of-retail-services-and-global-products-businesses/ Tue, 12 Oct 2021 12:00:00 +0000 https://selagylaw.com/valvoline-to-continue-separation-of-retail-services-and-global-products-businesses/ LEXINGTON, Ky., 12 October 2021 / PRNewswire / – Valvoline Inc. (NYSE: VVV), a global vehicle maintenance leader fueling the future of mobility with innovative products and services, today announced it is accelerating its transformation continues by continuing to separate its two business segments, Retail Services and Global Products. “Following a comprehensive review of strategic […]]]>

LEXINGTON, Ky., 12 October 2021 / PRNewswire / – Valvoline Inc. (NYSE: VVV), a global vehicle maintenance leader fueling the future of mobility with innovative products and services, today announced it is accelerating its transformation continues by continuing to separate its two business segments, Retail Services and Global Products.

“Following a comprehensive review of strategic alternatives by the board of directors and general management of Valvoline, we believe that a separation of our business segments will create significant and lasting value for our shareholders, employees and other stakeholders, and best position Retail Services and Global Products for continued long-term success, ”said Stephen F. Kirk, President of the council.

Sam mitchell, CEO, added: “Our confidence in separating these two strong businesses reflects the significant progress we have made in our strategic transformation. Retail Services now generates more than half of our adjusted EBITDA and is growing at an exceptional rate. The separation will allow Retail Services to continue to grow and focus on operating its world-class service model. Global Products is a market-leading, cash-generating company that we believe will thrive in the future with the ability to focus and allocate capital to its own strategic priorities. “

Valvoline works with its outside advisors to determine the best way to accomplish the separation. No timeline has been set for the completion of the separation, and Valvoline does not intend to disclose any further developments regarding this process, unless and until its board of directors approves a transaction. or a specific action.

Valvoline will publish its financial results for fiscal year 2021 on November 3, 2021. Based on the information currently available, the company plans to report sales of $ 3 billion for the 2021 financial year, up 27% compared to the previous year. Valvoline also currently expects Adjusted EBITDA and Adjusted EPS for fiscal 2021 to be within the forecast range for each measure, as shown in the company’s earnings announcement on. August 4, 2021. In addition, based on information currently available, Retail Services ended the year with 1,595 system-wide stores, and the company estimates that Retail Services experienced same-store sales growth across the system. system in the fourth quarter and the whole year by 20% and 21%, respectively, compared to the same periods of the previous year.

Retail Services Segment Overview
The Retail Services segment serves the passenger car and light truck rapid lubricants market by United States and Canada with a wide range of preventive maintenance services and capabilities performed through Valvoline’s retail network, independent and independent franchise stores operated by the company, and Express Care stores that service vehicles with Valvoline products. Valvoline operates the second largest rapid lubrication service chain by number of stores in United States with instant Valvoline oil changeSM and the third largest rapid lubrication service chain in Canada with the brand Valvoline Great Canadian Oil Change. On the strength of its strong reputation and a loyal and growing customer base, Valvoline believes that the Retail Services activity is well positioned to pursue exceptional growth and operational excellence. Based on currently available information, the Company expects to report Retail Services segment sales of $ 1.2 billion for fiscal year 2021, up 38% compared to the previous year.

Global Product Segment Overview
Present in more than 140 countries and territories, Valvoline’s Global Products segment sells lubricants and other automotive and engine care products primarily to automotive retailers, installers and original equipment manufacturers (OEMs). Valvoline has established itself as the world’s leading supplier of battery fluids to electric vehicle manufacturers, offering tailor-made products to help extend the range and efficiency of vehicles. In the United States, Valvoline is the third-largest brand of motor oil in the DIY market by volume. The company is low capital intensive and stands out from the competition because of its leading brand, the quality of its products and its strong distribution partnerships. Based on the information currently available, the Company expects to report sales of the Global Products segment of $ 1.8 billion for fiscal year 2021, up 20% compared to the previous year.

Advisers
Goldman Sachs & Co. LLC acts as financial advisor and Cravath, Swaine & Moore LLP acts as legal advisor to Valvoline.

About ValvolineMT
Valvoline Inc. (NYSE: VVV) is a global leader in vehicle maintenance fueling the future of mobility through innovative products and services for vehicles equipped with electric, hybrid and internal combustion powertrains. Founded in 1866, the company introduced the world’s first branded motor oil and has developed strong brand recognition and customer satisfaction ratings over the years across multiple service and product channels. The Company operates and franchises approximately 1,600 service center locations and is the # 2 and # 3 largest chain in the United States and Canada, respectively, by number of stores. With sales in more than 140 countries and territories, Valvoline’s solutions are available for every engine and transmission, including high-mileage vehicles and heavy-duty vehicles, and are offered at more than 80,000 locations worldwide. Creating the next generation of advanced automotive solutions, Valvoline has established itself as the world’s leading supplier of battery fluids to electric vehicle manufacturers, offering tailor-made products to help extend vehicle range and efficiency. To find out more or to find a Valvoline service center near you, visit valvoline.com.

Key trade measures
Valvoline tracks its operational performance and manages its business using certain key business metrics including system-wide store count and system-wide comparable store (“SSS”) sales. Management believes that these measures are useful in evaluating and understanding Valvoline’s operating performance and should be viewed as additions and not substitutes for sales or operating and net income of Valvoline, as determined in accordance with GAAP. United States.

While Valvoline does not recognize store level sales of franchised stores as sales in its consolidated statements of income, management believes that the SSS comparisons and the number of stores system-wide are useful in assessing the position on the market relative to competitors and the overall operational performance of stores and segments. System-wide SSS is defined as the sales of US retail service stores (company-operated and franchisee), with new stores, including franchise conversions, excluded from the measure until at the end of their first full financial year of operation, as this period is generally required. for new store sales levels to begin to normalize.

Forward-looking statements
Certain statements in this press release, other than statements of historical fact, including estimates, projections and statements relating to the business plans and results of operations of Valvoline, are forward-looking statements within the meaning of the law. Private Securities Litigation Reform Act of 1995. Valvoline has identified some of these forward-looking statements containing words such as “expects”, “estimates”, “expects”, “estimates”, “is likely”, “predicted”, ” projects “,” forecasts “,” may “,” “,” “should” and “intends” and the negative of these words or other comparable terminology. These forward-looking statements are based on expectations, estimates, current projections and assumptions of Valvoline at the date on which these statements are made and are subject to risks and uncertainties which may lead to results materially different from those expressed or implied in the forward-looking statements. ves. . Additional information regarding these risks and uncertainties is described in documents filed by the Company with the Securities and Exchange Commission (the “SEC”), including in “Risk Factors”, “Management’s Discussion and Analysis on financial position and results of operations ”and“ and Qualitative Disclosures about Market Risk ”of the latest periodic reports filed by Valvoline on Forms 10-K and 10-Q, which are available on the Valvoline website at http://investors.valvoline.com/sec-filings or on the SEC website at http://sec.gov. Valvoline assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future, except as required by law.

MT Brand, Valvoline or its subsidiaries, registered in various countries
SM Service mark, Valvoline or its subsidiaries, registered in various countries

FOR MORE INFORMATION

Sean T. Cornett
Senior Director, Investor Relations
+1 (859) 357-2798
[email protected]

Michèle Gaither Sparks
Senior Director, Corporate Communications
+1 (859) 230-8097
[email protected]

Jamie Tully/Warren rizzi/Devin Broda
[email protected]

SOURCE Valvoline Inc.

Related links

http://www.valvoline.com


Source link

]]>
MassRoots announces its intention to adopt a new corporate name “Greenwave Technology Solutions, Inc.” https://selagylaw.com/massroots-announces-its-intention-to-adopt-a-new-corporate-name-greenwave-technology-solutions-inc/ Tue, 12 Oct 2021 11:11:00 +0000 https://selagylaw.com/massroots-announces-its-intention-to-adopt-a-new-corporate-name-greenwave-technology-solutions-inc/ New company name emphasizes environmental technology NORFOLK, Virginia, October 12, 2021– (COMMERCIAL THREAD) – MassRoots, Inc. (“MassRoots” or the “Company”) (OTCPink: MSRT) is pleased to announce its intention to change its corporate name to “Greenwave Technology Solutions, Inc.” (“Greenwave”) following the recent closing of its acquisition of Empire Services, Inc. (“Empire”). As part of the […]]]>

New company name emphasizes environmental technology

NORFOLK, Virginia, October 12, 2021– (COMMERCIAL THREAD) – MassRoots, Inc. (“MassRoots” or the “Company”) (OTCPink: MSRT) is pleased to announce its intention to change its corporate name to “Greenwave Technology Solutions, Inc.” (“Greenwave”) following the recent closing of its acquisition of Empire Services, Inc. (“Empire”). As part of the name change, Greenwave has released a new corporate logo and plans to launch a new corporate website in the coming days. Although the legal name of the company will continue to be MassRoots, Inc. until the name change process is complete, for marketing and branding purposes the company will now begin to refer to itself. and will operate under the new company name.

“This is a new start for the company and under my leadership we will relentlessly focus on growing our revenues and improving our bottom line,” said Danny Meeks, President and CEO of Greenwave. “Steel is one of the most recycled materials in the world and over the past three decades the steel industry has been able to achieve significant reductions in energy intensity and greenhouse gases through recycling.(1). We believe the name Greenwave emphasizes our focus on environmental technologies and our commitment to constant progress. “

Greenwave recently acquired its 11e metal recycling facility, located in Virginia Beach, Virginia. It’s one of only two junkyards in Virginia Beach, the state’s largest city, and is slated to open under Greenwave management on or around October 18, 2021.

In the coming weeks, Greenwave intends to apply to be listed on the NASDAQ or the NYSE, which the Company believes will result in a significant increase in visibility, liquidity and institutional interest in its stock.

  1. According to the World Steel Association and the Canadian Sheet Steel in Construction Authority (see https://www.worldsteel.org/steel-by-topic/sustainability/materiality-assessment/recycling.html; and https://cssbi.ca/mid-rise-construction/sustainable-steel).

About Greenwave

MassRoots, Inc., which changes its name to Greenwave Technology Solutions, Inc., through its wholly owned subsidiary Empire Services, Inc. (“Empire”), is a major operator of 10 recycling facilities of metals in Virginia and North Carolina. At these facilities, Empire collects, classifies and processes raw scrap (ferrous and non-ferrous) for recycling. Steel is one of the most recycled products in the world with the ability to be remelted and remelted multiple times while providing significant economic and environmental benefits over virgin materials.

The company has announced its intention to change its legal name from MassRoots, Inc. to Greenwave Technology Solutions, Inc. Although the legal name of the company will continue to be MassRoots, Inc. until the name change process. be completed, for marketing and branding purposes, the company began doing business under the Greenwave name.

Forward-looking statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding its name change and a listing on a premier stock exchange. rank. These statements are identified by the use of the words “could”, “believe”, “anticipate”, “intend to”, “estimate”, “expect”, “could”, “continue”, “predict”. “,” Project “and similar expressions intended to identify forward-looking statements. All forward-looking statements speak only as of the date of this press release. You should not place undue reliance on these forward-looking statements. Although we believe that our plans, objectives, expectations and intentions reflected or suggested by forward-looking statements are reasonable, we cannot guarantee that these plans, objectives, expectations or intentions will be achieved. Forward-looking statements involve significant risks and uncertainties (some of which are beyond our control) and assumptions that could cause actual results to differ materially from historical experience and current expectations or projections. Actual results may differ materially from those of forward-looking statements and the price of our common shares may fluctuate significantly. Forward-looking statements are also affected by risk factors described in our filings with the United States Securities and Exchange Commission. Except as required by law, we assume no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unforeseen events. events.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211012005328/en/

Contacts

Isaac dietrich
(303) 816-8070
Isaac@MassRoots.com


Source link

]]>
Shulman Rogers Expands Divorce and Family Law Practice with Alisa Yasin and Amanda Gilbert https://selagylaw.com/shulman-rogers-expands-divorce-and-family-law-practice-with-alisa-yasin-and-amanda-gilbert/ Tue, 12 Oct 2021 11:00:00 +0000 https://selagylaw.com/shulman-rogers-expands-divorce-and-family-law-practice-with-alisa-yasin-and-amanda-gilbert/ Commenting on the growing team, the President of the Divorce and Family Law Division, Heather mehigan, shares: “Alisa and Amanda are widely regarded as exceptional and competent family law practitioners. They will bring tremendous added value to our customers, and we are delighted to welcome them. Shulman rogers. “ Alisa yasin is a strong advocate […]]]>

Commenting on the growing team, the President of the Divorce and Family Law Division, Heather mehigan, shares: “Alisa and Amanda are widely regarded as exceptional and competent family law practitioners. They will bring tremendous added value to our customers, and we are delighted to welcome them. Shulman rogers. “

Alisa yasin is a strong advocate for his clients, dealing with all areas of family law including adoption, assisted reproduction technologies, child custody, child support, child support investigations, child protection and all aspects of divorce cases. Although a strong supporter of working together to resolve family disputes, Alisa is ready to fiercely defend the financial, business and personal interests of her clients through legal intervention when dispute avoidance methods fail. She draws on her extensive experience in the public service when dealing with complex custody cases, including those involving allegations of child abuse and / or neglect, when she passionately advocates for parents and children in a crisis situation.

Amanda gilbert represents individuals in all aspects of family law, including divorce, custody, adoption and assisted reproduction techniques. She strives to help clients regain control of often overwhelming situations and develops creative solutions to help them achieve their goals. A qualified mediator and collaborative practitioner, Amanda is currently President-Elect of the DC Academy of Collaborative Professionals and a member of other Collaborative Dispute Resolution organizations. She believes that many family matters can (and should) be handled outside the courtroom, through mediation, the collaborative process or negotiated settlements, but she is always ready to represent her clients in the courtroom. hearing when litigation is unavoidable.

On Shulman rogers
Shulman rogers is a regional and national law firm, providing its clients with a full range of commercial and personal legal services. The firm’s experienced lawyers provide sophisticated and comprehensive advice to clients, including real estate, litigation, business, intellectual property, employment, start-up, as well as a host of personal services such as family law and estates and trusts. Further information on Shulman rogers and his areas of practice is available at ShulmanRogers.com

THE SOURCE Shulman rogers


Source link

]]>
NRx Pharmaceuticals Announces Progress in Global Commercial Development of ZYESAMI ™ (aviptadil) https://selagylaw.com/nrx-pharmaceuticals-announces-progress-in-global-commercial-development-of-zyesami-aviptadil/ Tue, 12 Oct 2021 10:48:00 +0000 https://selagylaw.com/nrx-pharmaceuticals-announces-progress-in-global-commercial-development-of-zyesami-aviptadil/ As thousands of people around the world continue to die from COVID-19 every day, we continue our efforts to ensure NRx has the supply and logistics to deliver ZYESAMI to patients where it has been approved. regulatory, ”said Professor Jonathan Javitt. , MD, MPH, CEO and President of NRx. Tweet this “As thousands of people […]]]>

“As thousands of people around the world continue to die from COVID-19 every day, we continue our efforts to ensure that NRx has the necessary supplies and logistics to deliver ZYESAMI to patients where it was obtained. regulatory approval, ”said the professor Jonathan javitt, MD, MPH, CEO and President of NRx.

About ZYESAMI ™ / VIP in COVID-19
Aviptadil is a synthetic form of vasoactive intestinal polypeptide (VIP), first discovered by the late Prof. Sami Said in 1970, and ZYESAMI ™ is named in his honor. Although primarily concentrated in the lungs, it was first purified from the intestinal tract. VIP binds specifically to the type II alveolar cell (ATII) in the air sac (alveolus) of the lung, where it has been shown to have potent anti-inflammatory / anti-cytokine activity in animal models of distress respiratory, acute lung injury, and inflammation. Most importantly, VIP stimulates ATII cells to make the surfactant that must cover the lining of the lungs so that they exchange oxygen with the blood. The loss of surfactant causes respiratory failure and alveolar collapse, which are hallmarks of COVID-19.

Respiratory failure associated with COVID-19 is caused by selective infection of the ATII cell with the SARS-CoV-2 virus. ATII cells are vulnerable due to their surface receptors (ACE2), which serve as the entry route for the virus. Coronavirus infection of the ATII cell stops surfactant production, triggers the formation of inflammatory cytokines, and causes cell death (cytopathy). VIP has been shown to upregulate surfactant production, block coronavirus replication in the ATII cell, block cytokine synthesis, and prevent virus-induced cell death (cytopathy). Other than ZYESAMI ™, no currently proposed treatment for COVID-19 specifically targets this mechanism of action.

About NRx Pharmaceuticals
NRx Pharmaceuticals (NRx) draws on more than 300 years of collective, scientific and drug development experience to improve patient health. Its investigational product, ZYESAMI ™ (aviptadil) for patients with COVID-19, has received Fast Track designation from the United States Food and Drug Administration (FDA) and is currently in phase 3 funded trials. by the United States National Institutes of Health, the Biomedical Advanced Research and Development Authority, part of the United States Department of Health and Human Services, and the Medical Countermeasures Program, part of the United States Department of Defense. The FDA further granted a breakthrough therapy designation, a special protocol agreement, and a letter of biomarker support to NRx for NRX-101, an investigational drug to treat suicidal bipolar depression. NRX-101 is currently in phase 3 trials, with readings expected in 2022. In July 2021, the government of Israel granted NRx the exclusive worldwide right to develop and market the BriLife ™ COVID vaccine developed by the Institute. Israeli biological research.

NRx is led by executives who have held leadership positions at Allergan, J&J, Lilly, Novartis, Pfizer and the US FDA. NRx is chaired by Professor Jonathan Javitt, MD, MPH, who has held leadership positions in six start-up biotech companies with public outings and has been appointed to advisory roles in four US presidential administrations. NRx’s Board of Directors includes Dr Sherry Glied, former Assistant Secretary of Health of the United States (ASPE), Daniel E. Troy, JD, former Chief Legal Officer of the US FDA, Chaim Hurvitz, former Director of Teva and Chairman of Teva International Group, and General HR McMaster, Ph.D. (US Army, Ret.) The 26th United States National Security Advisor.

Caution Regarding Forward-Looking Statements
This announcement by NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our outlook, product development, business outlook and market and industry trends and conditions, as well as corporate strategies, plans, objectives and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts and projections, as well as on assumptions made by the management of the company and on information currently available to it.

The company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Therefore, you should not rely on any forward-looking statements, and all forward-looking statements are qualified herein by reference to the cautionary statement.

SOURCE NRx Pharmaceuticals


Source link

]]>
Merck Launches Takeover Offer to Acquire Acceleron Pharma Inc. | Business https://selagylaw.com/merck-launches-takeover-offer-to-acquire-acceleron-pharma-inc-business/ Tue, 12 Oct 2021 10:46:56 +0000 https://selagylaw.com/merck-launches-takeover-offer-to-acquire-acceleron-pharma-inc-business/ KENILWORTH, NJ – (BUSINESS WIRE) – October 12, 2021– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today launches, through a subsidiary, a cash takeover bid to purchase all of the shares outstanding ordinary shares of Acceleron Pharma Inc. (Nasdaq: XLRN). On September 30, 2021, Merck announced that it had entered […]]]>

KENILWORTH, NJ – (BUSINESS WIRE) – October 12, 2021–

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today launches, through a subsidiary, a cash takeover bid to purchase all of the shares outstanding ordinary shares of Acceleron Pharma Inc. (Nasdaq: XLRN). On September 30, 2021, Merck announced that it had entered into a definitive agreement to acquire Acceleron.

Upon successful closing of the takeover bid, Acceleron shareholders will receive $ 180 in cash for each Acceleron Common Share validly deposited and not validly withdrawn from the Offer, without interest and less any required withholding tax. Following the purchase of shares as part of the public tender offer, Acceleron will become a subsidiary of Merck.

Merck will file today with the United States Securities and Exchange Commission (the “SEC”) a tender offer statement on Schedule TO, which provides the terms of the takeover bid. In addition, Acceleron will file with the SEC a solicitation / recommendation statement on Schedule 14D-9 which includes the recommendation of the Board of Directors of Acceleron that their shareholders accept the takeover bid and tender their shares.

The take-over bid will expire at 5:00 p.m. Eastern Time on November 10, 2021, unless extended in accordance with the merger agreement and applicable SEC rules and regulations. The closing of the tender offer is subject to certain conditions, in particular the contribution of shares representing at least the majority of the total number of Acceleron shares outstanding, the obtaining of the applicable regulatory approvals and of other usual conditions. The transaction is expected to be finalized in the fourth quarter of 2021.

About Merck

For more than 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, providing drugs and vaccines for many of the world’s most difficult diseases as part of our mission to save and improve lives. We demonstrate our commitment to patients and the health of the population by increasing access to health care through broad policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company. in the world. For more information visit www.merck.com and connect with us on Twitter, Facebook, Instagram, Youtube and LinkedIn.

Important information about the public tender offer

This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Acceleron Pharma Inc. (“Acceleron”) common stock or any other security, nor does it replace the tender offer documents described herein. A tender offer statement on Schedule TO, including an offer to purchase, transmittal letter and related documents, will be filed today by Merck Sharp & Dohme Corp. (“Merck”) and Astros Merger Sub, Inc., a wholly owned subsidiary of Merck, with the Securities and Exchange Commission (the “SEC”), and a solicitation / recommendation statement on Schedule 14D-9 will be filed by Acceleron with the SEC.

INVESTORS AND SECURITYHOLDERS ARE URGED TO CAREFULLY READ THE OFFER TO PURCHASE DOCUMENTS (INCLUDING AN OFFER TO PURCHASE, RELATED LETTER OF TRANSMITTER AND CERTAIN OTHER OFFER TO PURCHASE DOCUMENTS) AND THE DECLARATION OFFERING SOLICITATION / RECOMMENDATION 14D-9 MAY CHANGE FROM TIME TO TIME BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND HOLDERS MUST CONSIDER BEFORE MAKING ANY DECISIONS REGARDING THE OFFERING OF THEIR SECURITIES.

Investors and securityholders may obtain a free copy of the Offer to Purchase, the related Letter of Transmittal, certain other documents relating to the Takeover Offer and the Solicitation / Recommendation Statement ( when available) and other documents filed with the SEC on the website maintained by the SEC. To www.sec.gov or by directing such requests to the Offer Information Agent, who will be named in the tender offer statement. In addition, Merck and Acceleron file annual, quarterly, and current reports and other information with the SEC, which are available to the public from commercial document search services and on the SEC’s website at www.sec.gov. Copies of documents filed with the SEC by Merck can be obtained free of charge from Merck’s website at www.merck.com or by contacting Merck at 2000 Galloping Hill Road, Kenilworth, NJ 07033 or (908) 740-4000. Copies of documents filed with the SEC by Acceleron can be obtained free of charge from the Acceleron website at www.acceleronpharma.com or by contacting Acceleron at 128 Sidney Street, Cambridge, MA 02139 or (617) 649-9200.

Forward-looking statement by Merck & Co., Inc., Kenilworth, NJ, United States

This press release from Merck & Co., Inc., Kenilworth, NJ, United States (the “Company”) includes statements that are not statements of historical fact or “forward-looking statements”, including with regard to concerns the company’s proposed acquisition of Accéléron. These forward-looking statements include, without limitation, the ability of the Company and Acceleron to complete the transactions contemplated by the merger agreement, including the ability of the parties to meet the conditions of consumption of the contemplated offering. by it and the other conditions set out in the merger agreement, the statements on the expected timetable for the completion of the transaction, the opinions and expectations of the company and Acceleron and the statements on the benefits sought in the project acquisition of Acceleron by the company, the potential effects of the acquisition on both the company and Acceleron, the possibility of a possible termination of the merger agreement, as well as the expected profits and success of the product candidates from Acceleron. These statements are based on the current beliefs and expectations of the management of the company and are subject to significant risks and uncertainties. There can be no assurance that the conditions for closing the proposed transaction will be met on schedule or at all, with respect to pipeline products, that the products will receive the necessary regulatory approvals or that they will be met. will prove to be commercially successful. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements.

Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the Offer and the subsequent Merger; uncertainties as to the number of Acceleron shareholders who will tender their shares to the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions for the completion of the merger and the offer contemplated by it may not be met or removed; the effects of the transaction disruption contemplated by the merger agreement and the impact of the announcement and pending transaction on Acceleron’s business; the risk that a dispute between shareholders in connection with the offer or the merger could result in significant defense, indemnification and liability costs; general industry conditions and competition; general economic factors, including fluctuations in interest rates and exchange rates; the impact of the global novel coronavirus disease (COVID-19) epidemic; the impact of pharmaceutical industry regulation and health care legislation in the United States and globally; global trends towards containing health care costs; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of patents and other corporate protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions.

The company assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and other available SEC filings. on the SEC website ( www.sec.gov ).

View source version on businesswire.com:https://www.businesswire.com/news/home/20211012005308/en/

CONTACT: Media contacts: Patrick Ryan

(973) 275-7075 Melissa Moody

(215) 407-3536 Investor contacts: Peter Dannenbaum

(908) 740-1037Steven Graziano

(908) 740-6582

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY PHARMACEUTICAL RESEARCH MEDICAL SUPPLIES GENERAL HEALTH HEALTH CLINICAL TRIALS

SOURCE: Merck & Co., Inc.

Copyright Business Wire 2021.

PUB: 12/10/2021 06:45 / DISC: 12/10/2021 06:46

http://www.businesswire.com/news/home/20211012005308/en



Source link

]]>
Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Scientific Director of Johnson & Johnson to retire effective December 31, 2021 https://selagylaw.com/dr-paul-stoffels-vice-chairman-of-the-executive-committee-and-scientific-director-of-johnson-johnson-to-retire-effective-december-31-2021/ Tue, 12 Oct 2021 10:45:00 +0000 https://selagylaw.com/dr-paul-stoffels-vice-chairman-of-the-executive-committee-and-scientific-director-of-johnson-johnson-to-retire-effective-december-31-2021/ NEW BRUNSWICK, NJ, 12 October 2021 / PRNewswire / – Johnson & Johnson (NYSE: JNJ) today announced that Paul Stoffels MD., currently Vice-Chairman of the Executive Committee and Scientific Director of Johnson & Johnson, will retire from the Company as of December 31, 2021. As Vice Chairman of the Executive Committee and Scientific Director, Dr […]]]>

NEW BRUNSWICK, NJ, 12 October 2021 / PRNewswire / – Johnson & Johnson (NYSE: JNJ) today announced that Paul Stoffels MD., currently Vice-Chairman of the Executive Committee and Scientific Director of Johnson & Johnson, will retire from the Company as of December 31, 2021.

As Vice Chairman of the Executive Committee and Scientific Director, Dr Stoffels led the company’s research and product pipeline teams across all industries to define the company-wide mandate to discover and to develop transformational healthcare solutions. Under his leadership, Johnson & Johnson revitalized its innovation pipeline and created one of the strongest portfolios in the industry. As a strong advocate for solving some of the world’s most difficult health challenges, Dr Stoffels has relentlessly focused on unleashing the power of science and research and development innovation ( R&D) internal and external innovation to develop medicines and solutions for people all over the world. world.

“It has been an honor and privilege to lead Johnson & Johnson’s innovation agenda and to propel transformational innovation to deliver years of life and quality of life to millions of people around the world,” said the Dr Stoffels. “As a physician and scientist, it is gratifying to see the healthcare landscape transform as we unlock the best science and technology to deliver innovative medicines to solve the world’s most difficult health problems. As I reflect on the work of our talented and dedicated teams around the world, I am proud of the impact we have had and confident that our vibrant community of world-renowned scientists and engineers will position our company for continued success. . “

Committed to driving innovation and collaborating on the best science and technology, Dr Stoffels has created Johnson & Johnson Innovation – a vast network of innovation hotspots across the world – as a critical source to access to the best sciences and technologies thanks to strategic partnerships, licenses, acquisitions, incubation and investments. Today there are over 700 incubating companies in the JLABS ecosystem, countless strategic partnerships through Innovation Centers and many significant strategic investments through Johnson & Johnson Innovation – JJDC, Inc., the strategic arm. Johnson & Johnson venture capital fund.

“Paul is an exceptional human being, inspiring people every day. His remarkable ability to bring a vision and mission to life, and his commitment to improving and saving lives on a global scale, have moved the organization forward and generated enormous impact on global health and on the trajectory of Johnson & Johnson, ”said Alex gorsky, currently President and CEO of Johnson & Johnson. “Working with Johnson & Johnson’s senior R&D managers on the R&D Management Committee, Paul created a culture of people development, sponsorship, entrepreneurial leadership, developing generations of talented new leaders for Johnson & Johnson. Johnson. “

Previously, in his role as Global President of Pharmaceuticals, Dr Stoffels led the transformation of the pharmaceutical research and development pipeline for the Janssen Pharmaceutical Companies of Johnson & Johnson, resulting in a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Paul has also played a key role in numerous collaborations with external partners, including the licensing of key drugs, as well as the acquisition of Crucell and Actelion.

“With Paul at the helm, Janssen has rejuvenated its pipeline, launching several new drugs, making a difference for people around the world,” said Joaquin duato, vice chairman of the executive committee and next CEO of Johnson & Johnson from January 3, 2022. “Under Paul’s leadership, Janssen’s R&D teams have developed more than 25 new drugs in several therapeutic areas. Seven of these drugs have been added to the World Health Organization’s Essential Medicines List, a recognition of the tremendous impact these drugs are having on patients globally. ”

Dr Stoffels is a recognized global leader in the world of public health. By relentlessly focusing on treating and eliminating HIV, tuberculosis and Ebola, the world’s most devastating infections, his teams have developed drugs and vaccines. He founded Johnson & Johnson Global Public Health with a mission to make a difference for people in low- and middle-income countries. In 2020, he led the development of Johnson & Johnson’s single injection COVID-19 vaccine in record time. The vaccine is an essential tool in the fight against the pandemic for people living in low-income countries.

Paul is also a leading thought leader in the global public health arena, advancing key global health policy goals by representing Johnson & Johnson to organizations such as the Bill & Melinda Gates Foundation, the National Institutes of Health, the Innovative Medicines Initiative of the European Commission and World Health Organization. Paul was instrumental in founding TransCelerate Biopharma Inc., the Dementia Discovery Fund and other pre-competitive collaborations aimed at fueling investments in innovation and accelerating solutions for patients.

“I look forward to working with Alex and Joaquin to ensure a smooth transition for our R&D and innovation teams,” said Stoffels. “With vi years of life and quality of life for people around the world.”

On Paul Stoffels, MD

Paul studied medicine at the University of Diepenbeek and the University of Antwerp in Belgium and infectious diseases and tropical medicine at the Institute of Tropical Medicine in Antwerp, Belgium.

Paul began his career as a physician in Africa, focusing on clinical research in HIV and tropical diseases, and worked at Janssen Pharmaceutica under the tutelage of Dr. Paul Janssen in the early 1990s. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he led the development of several breakthrough products for the treatment of HIV that have helped turn this devastating and deadly disease into one. chronic and treatable disease.

About Johnson & Johnson
At Johnson & Johnson, we believe that good health is the foundation for vibrant lives, thriving communities and progress into the future. That’s why, for more than 130 years, we’ve strived to keep people healthy at all ages and at all stages of life. Today, as the world’s largest and most widely used healthcare company, we’re committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and make a healthy mind, body and environment available to everyone, everywhere. We combine our heart, our science and our ingenuity to profoundly change the trajectory of human health.

Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 concerning, among other things, future operational and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If the underlying assumptions prove to be incorrect or if known or unknown risks or uncertainties materialize, actual results could differ materially from Johnson & Johnson’s expectations and projections. Risks and uncertainties include, but are not limited to: risks related to the impact of the global COVID-19 pandemic, such as the extent and duration of the outbreak, government actions and restrictive measures implemented. work in response, significant delays and cancellations of medical procedures, supply chain disruptions and other impacts on the business, or on the Company’s ability to execute business continuity plans, due to from the COVID-19 pandemic, from economic factors, such as fluctuations in interest rates and exchange rates; competition, including technological advances, new products and patents obtained by competitors; challenges inherent in the research and development of new products, including the uncertainty of clinical success and obtaining regulatory approvals; the uncertainty of the commercial success of new and existing products; patent challenges; the impact of patent expirations; the Company’s ability to successfully execute its strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety issues resulting in product recalls or regulatory action; material adverse litigation or government actions, including related to product liability claims; changes in applicable laws and regulations, including tax laws and global healthcare reforms; trends towards containing health care costs; changes in the behavior and spending patterns of buyers of health care products and services; the financial instability of economies and international legal systems and sovereign risk; increased oversight of the health care sector by government agencies. A list and additional descriptions of these risks, uncertainties and other factors are available in Johnson & Johnson’s annual report on Form 10-K for the year ended. January 3, 2021 including in the sections entitled “Caution Regarding Forward-Looking Statements” and “Section 1A. Risk Factors ”in the Company’s latest Quarterly Report on Form 10-Q and subsequent Company filings with the Securities and Exchange Commission. Copies of these documents are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statements made in this press release speak only as of the date of this press release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

###

SOURCE Johnson & Johnson

Related links

https://www.jnj.com/


Source link

]]>